Mortality rate and predictors among stroke patients in the public hospitals in Harari region, Eastern Ethiopia

埃塞俄比亚东部哈拉里地区公立医院中风患者的死亡率及其预测因素

阅读:2

Abstract

Stroke is a major cause of death and disability worldwide, yet there is limited information on the mortality rate and its predictors in Eastern Ethiopia. This lack of evidence is particularly significant, as hospitals in the Harari region provide the majority of healthcare services for stroke and chronic diseases. Therefore, our objective is to assess the mortality rate and predictors among stroke patients in the public hospitals in Harari. An institutional-based retrospective follow-up study was conducted among 452 randomly selected stroke patients at public hospitals in the Harari region from July 1, 2019, to June 30, 2024. The incidence of unfavorable treatment outcomes was calculated at 95% CI, and predictors of mortality were determined using Cox regression analyses. Of the 452 patients included, 292 (64.6%) improved, 21 (4.7%) were discharged with complications, 63 (13.9%) died, and 76 (16.8%) were discharged against medical advice. The 60-month follow-up revealed a mortality rate of 7.6 (95% CI: 5.9-9.7) per 1,000 person-months. The mortality risk was higher among stroke patients with hypertension (AHR: 2.0, 95% CI: 1.1-3.9), heart failure (AHR: 2.2, 95% CI: 1.1, 4.9), those with complications (AHR: 4.9, 95% CI: 1.5, 16.3), hospital-acquired infections (AHR: 3.1, 95% CI: 1.5-6.7), aspiration pneumonia (AHR: 1.9, 95% CI: 1.1-3.4), poor Glasgow Coma Scale (GCS) scores (AHR: 6.9, 95% CI: 2.4-19.9), and moderate impairment in GCS (AHR: 4.7, 95% CI: 1.6-13.3). Conversely, the use of antiplatelet drugs was associated with a reduced mortality risk in stroke patients (AHR: 0.5, 95% CI: 0.3-0.9). The mortality rate of stroke in this study was comparable to that of other studies in Ethiopia. Factors such as hypertension, heart failure, lower GCS, complications, aspiration pneumonia, and hospital-acquired infections increased mortality risks, while antiplatelet drugs reduced them. Therefore, strategies for early screening and follow-up of at-risk patients are essential.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。